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Abstract
SLC4A3 has been shown to cause retinal degeneration in a genetically engineered knockout mouse, and in a naturally
occurring form of canine progressive retinal atrophy considered to be the equivalent of retinitis pigmentosa in
humans (RP). This study was undertaken to investigate if SLC4A3 coding variants were implicated in human retinal
degeneration. SLC4A3 exons were amplified and sequenced in 200 patients with autosomal recessive retinal
degeneration who had no known molecular diagnosis for their condition, which included 197 unrelated individuals
with suspected RP and three individuals with other forms of retinal disease. Three rare variants were identified that
were predicted to be potentially pathogenic, however each variant was heterozygous in a single patient and therefore
not considered disease-causing in isolation. Of these three variants, SNP-3 was the rarest, with an allele frequency of
7.06x10−5 (>46,000 exomes from the ExAC database). In conclusion, no compound heterozygous or homozygous
potentially pathogenic variants were identified that would account for recessive RP or retinal degeneration in this cohort,
however the possibility remains that the rare variants identified could be acting with as yet undiscovered mutations in
introns or regulatory regions. SLC4A3 remains an excellent candidate gene for human retinal degeneration, and with the
advent of whole exome and whole genome sequencing of cohorts of molecularly unsolved patients with syndromic
and non-syndromic forms of retinal degeneration, SLC4A3 may yet be implicated in human disease.
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Introduction
SLC4A3 (solute carrier family 4, member 3; OMIM
106195), encodes the anion exchanger 3 (AE3) protein,
which mediates Cl−/HCO3
− exchange across cellular
membranes [1]. It is expressed in various tissues includ-
ing the Müller and horizontal cells of the retina [2], and
has been implicated in retinal disease in animals. A
knockout mouse model for Slc4a3 identified SLC4A3 as
a candidate gene for human vitreoretinal degenerations
based on their findings of blindness and retinal degener-
ation in knockout mice [3]. Slc4a3−/− mice at four
months of age had no gross retinal abnormalities; How-
ever, ERG analysis revealed an inner retina defect from
birth (reduced b-wave and flicker amplitudes), leading to
phototransduction failure at four months (reduced a-
wave amplitude). At 4–6 months the number of apop-
totic nuclei observed by TUNEL labelling increased. By
eight months, pathological signs of photoreceptor de-
generation were observed including dense astrocytic
processes wrapped around inner retina vessels (a feature
analogous to vascular sheathing seen in humans), small
diameter major blood vessels, disorganised astrocytic
processes at the optic nerve head and rod bipolar cell
dendrites aberrantly sprouted into the outer nuclear
layer [3].
In addition, we have previously shown that a mutation
in SLC4A3 is associated with a form of naturally occur-
ring autosomal recessive (AR) Progressive Retinal Atro-
phy (PRA) in the Golden Retriever dog breed, known as
GR_PRA1 [4]. We predicted that the homozygous
frame-shifting mutation we identified (c.2601_2602insC,
predicted to cause a premature stop codon in exon 18,
p.E868RfsX104), would result in the loss of a large sec-
tion of the transmembrane domain and entire C-
terminal cytoplasmic domain, including a number of
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putative carbonic anhydrase binding sites [4]. GR_PRA1
is phenotypically consistent with PRA in other breeds of
dog, which is characterized by nyctalopia (night blind-
ness), tapetal hyperreflectivity, retinal vascular attenu-
ation, pigmentary changes and atrophy of the optic
nerve head [5].
PRA is widely considered to be the veterinary equiva-
lent of Retinitis Pigmentosa (RP) in humans. RP is the
name given to a group of inherited retinal degenerations
which affects 1 in 3500 to 4500 people [6]. Photorecep-
tor cells predominantly affected are the rods and there-
fore clinical symptoms typically include nyctalopia and
loss of peripheral vision. With disease progression, the
cones also degenerate resulting in central vision loss and
eventually possibly complete blindness [7]. While this
heterogeneous group of diseases is highly variable with
regard to age of onset, retinal appearance, progression
and visual outcome, there are hallmark characteristics
secondary to photoreceptor degeneration. These include
“bone spicules” caused by pigment granule migration
from the retinal pigment epithelium and retinal arteriole
and vein attenuation [7]. Inheritance may be AR, auto-
somal dominant, X-linked (XL) or digenic. With 34 genes
implicated to date, AR is the most prevalent mode of in-
heritance [8]. While PRA is considered the equivalent of
RP, due to the limited clinical characterisation of retinal
degenerations in dogs, similar retinal diseases can be mis-
diagnosed as PRA. This suggests that a disease diagnosed
as PRA may, in some cases, represent a form of retinal de-
generation that is the equivalent of other forms of human
retinal dystrophy with similar ophthalmic phenotypes e.g.
Leber congenital amaurosis (LCA) or cone-rod dystrophy.
At least 17 naturally occurring dog models with retinal
degeneration have been described with equivalent hu-
man disease (reviewed in [9]). These are valuable, not
only for understanding disease pathology better, but also
for developing treatments. For example, mutations in
RPE65 have been implicated in AR retinal degeneration
(LCA) in dogs [10, 11] and humans [12, 13], and gene
therapy clinical trials have yielded promising results in
both species [14–20]. Similarly, mutations in RPGR
cause XLPRA [21–23] and are responsible for more than
70 % of XLRP cases [24–26]. Gene therapy strategies are
underway with promising results in the dog model [27].
Importantly, even though more than 200 genes have
been identified with mutations that cause retinal degen-
eration in humans, including forms of RP, it is estimated
that the genes involved in approximately 35 % of AR ret-
inal dystrophies remain unknown [28].
Two main isoforms of SLC4A3 have been described in
humans: a full-length (SLC4A3fl1) isoform comprised of
one non-coding (5’UTR) and 22 coding exons and a car-
diac (SLC4A3c) isoform with 18 coding exons [4, 29].
These alternative transcripts differ at the 5’ end (Fig. 1).
Alternative splicing of exon six of SLC4A3fl1 results in a
further isoform (SLC4A3fl2) that differs by 81 bp.
SLC4A3fl1 (Genbank: NM_201574.2) encodes a 1259
amino acid protein (Fig. 1), and this is the isoform re-
ferred to throughout the remainder of this manuscript.
SLC4A3fl2 (GenBank: NM_005070.3) is the shorter ver-
sion and encodes a protein of 1232 amino acids. In
SLC4A3c exon C1 replaces exons one to six of the full-
length transcripts, and encodes a smaller protein prod-
uct of 1034 amino acids [29]. A rare variant in the
SLC4A3 gene, Ala867Asp, has been associated with idio-
pathic generalized epilepsy (IGE) in humans, with car-
riers exhibiting an increased risk of developing IGE [30],
but SLC4A3 has not been implicated in human retinal
disease. Evidence from the mouse and canine disease
models suggest the SLC4A3 gene is an excellent candi-
date for human retinal degeneration. We therefore
screened SLC4A3 in a cohort of human patients with
predominantly recessive retinal degeneration currently
lacking a molecular diagnosis in order to determine
whether mutations in this gene cause a significant pro-
portion of retinal degeneration in humans.
Materials and methods
Study subjects
The recruitment of all patients was part of a study
protocol that adhered to the tenets of the Declaration of
Helsinki and had received approval from the Moorfields
Eye Hospital Research Ethics Committee. Written, in-
formed consent was obtained from all participants prior
to their inclusion in this study with parental written con-
sent provided on behalf of any minors involved.
Two hundred affected unrelated individuals ascer-
tained from the clinics of Moorfields Eye Hospital were
evaluated for SLC4A3 variants. Of these, 192 probands
were affected with progressive retinal degeneration, con-
sistent with a diagnosis of either retinitis pigmentosa or
cone-rod dystrophy with presentation in adulthood (dur-
ing or after the second decade). Eight additional patients
with various forms of retinal degeneration were also se-
lected for screening. In each of these 8 cases, autozygos-
ity mapping previously conducted at UCL Institute of
Ophthalmology (UCL, London) had identified large re-
gions of homozygosity that included the genomic region
containing SLC4A3, amongst other genes (Additional
file 1). All 200 probands were assessed by AW, ATM or
MM as part of their management in specialist inherited
retinal clinics. Diagnosis was determined through a pa-
tient’s presenting history, clinical examination, retinal im-
aging including autofluorescence imaging and optical
coherence tomography. Electroretinography was per-
formed in those patients with milder disease (it is not in-
formative in severe cases). Probands with a clinical history
or signs suggestive of syndromic retinal dystrophy such as
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Usher (I, II or III), Bardet Biedl, Refsum disease, Joubert
syndrome or Senior Loken syndrome for example were
not included in this cohort. The family history was com-
patible in all cases with autosomal recessive inheritance.
Simplex or male siblings in which X-linked retinal dys-
trophy was a possibility were screened for mutations in
RP2 and RPGR (including ORF15) and were negative.
Other candidate gene screening had been performed
on a subset of probands as part of other similar pro-
jects, but had not had screening for all known retinal
degeneration genes. Many probands, for instance, had
been sequenced as part of a study of USH2A-related
retinal dystrophy and those that were positive for
USH2A mutations were excluded from this cohort.
To our knowledge none of the patients had any other
complications or symptoms, including epilepsy, how-
ever the possibility that such symptoms were undiag-
nosed or verbally unreported by the patient cannot be
excluded. Normal healthy control samples were not
collected as part of this study. Instead, exome variant
data available for >46,000 individuals through the Ex-
ome Aggregation Consortium (ExAC) [31] was used
for control data.
Sequencing
Primers for amplification and sequencing of SLC4A3
exons (Additional file 2), based on the known transcripts
SLC4A3fl1 (GenBank: NM_201574.2), SLC4A3fl2(Gen-
Bank: NM_005070.3) and SLC4A3c [29] were designed
with Primer3 [32]. SLC4A3 exons were amplified by
PCR using HotStarTaq Plus DNA Polymerase (Qiagen)
in genomic DNA. PCR products were purified using
PCRμ96 filter plates (Millipore). Amplification products
were sequenced using BigDye Terminator v3.1 (Applied
Biosystems), and sequence product was purified using
the Montage SEQ96 Cleanup Kit (Millipore), then run
on an ABI 3730 Genetic Analyzer. Sequence traces
were assembled, analysed and compared with the
human reference sequence (GRCh37) using the Sta-
den Package [33].
Variant pathogenicity analysis
The potential pathogenicity of variants identified was
assessed with various bioinformatics tools (Additional file
3). The ExAC Browser was used to determine whether
any of the human variants discovered were novel and to
determine allele frequencies of those variants previously
identified. SIFT [34], PolyPhen2 [35] and PMut [36] were
used to assess potentially pathogenic variants. A splice site
prediction tool, NNSPLICE0.9 [37, 38], was used to iden-
tify any variants that may affect splicing.
Results
Sequencing of all known exons and intron-exon bound-
aries of SLC4A3 in 200 patients revealed 50 SNP variants
(Additional file 3) carried by at least one individual, but
no small insertions or deletions within exons, when
compared with the human reference sequence (GRCh37).
Of these, 21 were located in exons, 23 in introns, four in
the 5’-UTR and two in the 3’-UTR. The majority (n = 42)
have previously been identified and have entries in the
dbSNP database, and 31 are present in the Exome Aggre-
gation Consortium (ExAC) database. Copy number
variants, such as large deletions and insertions within in-
trons, or affecting upstream promoter sequences, were
not assessed in this study.
After elimination of variants that were unlikely to be
pathogenic due to allele frequency in the population
(>0.03) and/or prediction of pathogenicity, three rare
variants remained that were predicted to affect exon
splicing and/or change the amino acid sequence of the
protein (Table 1). SNP_1 affects only the full-length
SLC4A3 isoforms, while SNPs_2 and _3 affect the full-
length and cardiac isoforms (Fig. 2). Three patients from
the panel of 192 AR RP cases carried one of these three
variants in the heterozygous state.
Fig. 1 Genomic structure of the human SLC4A3 gene and AE3 protein isoforms. a The three isoforms of SLC4A3 are created by alternative splicing
of exons 1–6 and C1, and by alternative splicing of exon 6 (red). b AE3fl1 and AE3fl2 proteins are created from alternative splicing of exon 6 and
differ only with regards to the presence and absence respectively of 27 amino acids. AE3c is created by alternative splicing of exon C1 and the
first 72 amino acids are completely different than the full-length isoforms (grey). All three isoforms are identical over the 962 amino acids at the
C-terminal end
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SNPs_1 (c.758T>C, p.S253L) and _2 (c.G3674A,
p.R1225Q) are non-synonymous SNPs that result in
amino acid changes that are predicted to be pathogenic
by at least one of the in silico prediction tools (PolyPhen,
SIFT and PMut; Table 1). SNP_1 is predicted to affect
the full-length isoforms only and SNP_2 the full-length
and cardiac isoforms. SNP_2 is also predicted to affect
splicing of all three isoforms of the protein, with the po-
tential to introduce a new acceptor site (Fig. 3b). This
would result in the deletion of 49 amino acids near the
C-terminus of the protein. SNP_3 (c.G2865A, p.G955G)
is predicted to affect exon splicing, presumably, as it is
located 18 bp 3’ of the acceptor spice site, by affecting
an exon splicing enhancer. Due to its location in exon
18, SNP_3 would affect all three isoforms of the protein.
It is predicted to remove an existing acceptor site
(Fig. 3c), resulting in a reading frame shift, early termin-
ation codon, and loss of 269 amino acids.
These three rare variants all have potentially patho-
genic, loss-of-function effects on the AE3 protein. Each
variant was only detected in a single patient in the het-
erozygous state (Table 2). All three variants were also
heterozygous in a number of controls: SNP_1 in 146/
56,676 controls, SNP_2 in 93/60,187 controls and
SNP_3 in 8/46,201 controls. SNP_1 and SNP_2 were
each homozygous in one control. In addition no patients
carried more than one SLC4A3 variant.
Discussion
Despite the association of aberrant SLC4A3 with retinal
degeneration in two model species, mouse and dog,
similar studies investigating possible involvement of the
gene in human retinal degeneration have not been re-
ported to date. Of the 14 genes reported to be involved
in canine retinal degeneration [39], 11 have also been
implicated in human retinal disease [8]. It is therefore
possible, if not probable, that mutations in SLC4A3
could cause retinal disease in humans. We report here
the first such study to screen human patients with ret-
inal disease for potentially pathogenic mutations in the
SLC4A3 gene.
The full-length isoforms of AE3 are expressed pre-
dominantly in the brain, but it is also found in the gut,
kidney, heart and Müller cells of the retina [1, 2, 29, 40,
41]. The cardiac isoform is expressed predominantly in
the heart and also in the horizontal neurons of the retina
[1, 2, 41]. The structure of the protein is thought to be
similar to another family member, SLC4A1 (AE1). SLC4
proteins are made up of three structural domains. At the
N-terminus there is a hydrophilic, cytoplasmic domain
of between 400 and 700 amino acids, followed by a
hydrophobic, polytopic transmembrane domain of ap-
proximately 500 amino acids, comprising up to 14
transmembrane spans, and lastly a cytoplasmic do-
main of between 30 and 100 amino acids at the C-
terminal end [1, 40].
While SLC4A3 has not been directly linked with dis-
ease in humans, there is evidence that indicates the pro-
tein is vital to normal brain and cardiac function. The
p.Ala867Asp variant confers susceptibility to idiopathic
generalised epilepsy [30]. This variant results in de-
creased AE3 transport activity that could cause abnor-
mal intracellular pH and changes in cell volume, which
in turn may promote neuron hyperexcitability and the
generation of seizures [42]. The p.Ala867Asp variant was
not identified in any of the cases screened, nor has epi-
lepsy been reported in the current patient cohort. Never-
theless, we cannot exclude the possibility that epilepsy is
Table 1 Rare variants predicted to be potentially deleterious
SNPa ID Genomic
Location
A1b A2c Possible effect on splice sites Nucleotide
change
Codon
change
Reference SNP
(rs) ID
Predicted to be
Pathogenic byd
1 2:220494940 C T None c.758C>T S253L rs36068948 PP
2 2:220505656 G A Introduction of acceptor site (0.00-0.81) c.3674G>A R1225Q rs150952379 PP, S, PM, N
3 2:220502903 G A Loss of acceptor site (0.45-0.00) c.2865G>A G995G rs387907534 N
aSNP = single nucleotide polymorphism
bAllele 1 = Reference Allele
cAllele 2 = Minor/Variant Allele
dPP = PolyPhen; S = SIFT; PM = PMut; N = NNSPLICE
Fig. 2 Location of potentially pathogenic variants identified in RP patients on the AE3 protein. The number of amino acids that constitute each
protein domain are indicated. SNPs_2 and _3 are located in the domains shared by the full-length (b) and cardiac (c) isoforms. SNP_1 is located
in the N-terminal cytoplasmic domain unique to the full-length isoform (grey). SNP = single nucleotide polymorphism
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present, but has simply not been diagnosed, or reported
to us, in our patient cohort. Hentschke et al. described a
SLC4A3 knockout mouse that appeared healthy, but had
a reduced seizure threshold when exposed to bicuculline,
pentylenetetrazole or pilocarpine, and increased seizure-
induced mortality [43]. In addition, AE3c has a key role
in myocardial intracellular pH recovery from alkaline
loads [44]. While the loss of AE3 alone has no known
adverse effects on the heart, the combined loss of AE3
and sodium/potassium/chloride transporter 1 (NKCC1,
aka SLC12A2) impairs cardiac function [45]. Similarly,
loss of AE3 in the TM180 transgenic mouse (with a
Glu180Gly substitution in the α-tropomyosin gene) led
to more rapid decompensation and heart failure than
the TM180 mouse alone [46].
Screening of the exons of SLC4A3 in DNA samples
from 200 patients with retinal degeneration resulted in
the identification of three rare variants that are predicted
(by in silico methods) to be potentially deleterious.
Three individuals with AR RP carry one copy of the
minor allele at one of these loci (Table 2), i.e. are hetero-
zygous. The variants are therefore insufficient to cause
AR RP in isolation. None of the heterozygous individuals
were found to carry more than one rare SLC4A3 variant
and do not, therefore, appear to be compound heterozy-
gotes. However, in this study we did not evaluate non-
coding regions of the gene or exclude the possibility of
partial gene deletions of the other allele. In the same
way that the p.Ala867Asp variant predisposes patients to
epilepsy it is possible that one of the variants identified
in the present study predisposes patients to retinal de-
generation, perhaps only in conjunction with a mutation
at another location. Alternatively, a heterozygous muta-
tion could modify the penetrance or age of onset of ret-
inal degeneration caused by a mutation at another
location. Whole genome or exome sequencing could
identify a second hit at another locus, but is outside the
scope of the present study.
All three rare variants were also seen in the control
datasets. SNP_1 (c.758T>C, p.S253L) and SNP_2
Fig. 3 Predicted splicing effects of two exonic variants on the AE3 protein. Graphical representation of the wildtype human AE3 protein and the
predicted splicing effects of exonic variants on the protein. The numbers of amino acids are indicated, and the nucleotides affected by the
variants are flanked by square brackets. a Normal full-length (AE3fl1, 1259 amino acids) protein. b SNP_2 may introduce an acceptor site resulting
in the reduction in the size of exon 22 from 174 to 27 bp. This results would be an in-frame deletion of 49 amino acids near the C-terminus of
the protein, and a final protein 1210 amino acids in size. c SNP_3 may remove an acceptor site resulting in an increase in the size of exon 18 from
90 to 270 bp, which would result in an insertion of 41 amino acids (Ins), a premature termination codon, and the loss of 269 amino acids at the
C-terminus. SNP = single nucleotide polymorphism
Table 2 Variant frequency in patient and control cohorts
Variantsa 200 Patient Panel ExAC
SNP_IDb A1/A1 A2/A1 A2/A2 A2 Freq A1/A1 A2/A1 A2/A2 A2 Freq
1 199 1 0 0.003 56,529 146 1 0.001
2 199 1 0 0.003 60,093 93 1 7.89x10−4
3 199 1 0 0.003 46,193 8 0 8.66x10−5
aA1 = Reference Allele, A2 =Minor/Variant Allele, depicted in Bold
bSNP = single nucleotide polymorphism
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(c.3674G>A, p.R1225Q) were found in the homozygous
state in a single control exome each, as well as in the
heterozygous state in multiple exomes, at a frequency of
7.89x10−4 and 8.66x10−5 respectively. SNP_3 (c.2865G>A)
was found in the heterozygous state only at a frequency of
8.66x10−5. The relatively high frequency of SNP_1 in the
control exomes and the observation that it was predicted
to be potentially pathogenic by only one of the in silico
prediction tools suggests the variant is unlikely to play a
role in retinal disease. SNP_2 has a relatively high allele
frequency and occurs in the homozygous state in the con-
trol cohort. This suggests that this rare variant is also un-
likely to cause disease in isolation, even though this
variant was predicted to be potentially pathogenic by all
four in silico prediction tools. Finally, SNP_3 has a very
low allele frequency in the control exome data (8.66x10
−5), but is predicted to affect exon splicing only. The SNPS
predicted to affect exon splicing (SNPs_2 and _3; Fig. 3)
could be further investigated through analysis of mRNA
transcripts, if the transcripts are detected in easily access-
ible tissue such as blood or buccal cells. However, as we
have previously found that canine SLC4A3 mRNA is
undetectable in blood or buccal cells (unpublished data),
human SLC4A3 mRNA is also likely to be undetectable
and this was not pursued. In vitro assays could be useful
to assess pathogenicity of SNP variants. However, it is dif-
ficult to select which variants to test, and the assay to use
until more convincing evidence is presented that SLC4A3
is involved in human retinal disease. Such a study would
therefore be premature at this stage.
While it appears that the variants in SLC4A3 identified
in this study are unlikely to cause AR RP in the cohort
screened in isolation, we cannot fully exclude these vari-
ants or the gene as a candidate for retinal degeneration.
Potentially pathogenic rare variants in intronic regions
or upstream elements that were not screened for muta-
tions by sequencing could affect exon splicing or regula-
tion of gene expression. In addition, it is possible that
disease-causing mutations in this gene are extremely
rare and essentially private mutations affecting only one
or two affected individuals, as is increasingly the case in
consanguineous families with a recessive condition, and
that these individuals have yet to be screened. For ex-
ample, a PRCD gene mutation (p.C2Y) was reported to
cause PRA in dogs and RP in one person. However, no
other disease-causing mutations were found in PRCD in
a further 1240 RP patients screened [47]. Disease-
causing mutations in this gene are therefore exceedingly
rare in the general population. However, a second patho-
genic mutation in PRCD has since been identified in an
isolated Muslim Arab village in Northern Israel; This
founder mutation was homozygous in all 18 RP-affected
individuals, but not in any of the 28 unaffected family
members [48]. While the identification of cases caused
by mutations in other RP genes has been accelerated by
the use of exome sequencing, this has not been the case
for PRCD [49, 50]. Finally, it is also possible that mutant
SLC4A3 actually causes a syndromic or non-syndromic
form of retinal degeneration in humans that would not
be clinically classified as RP. Little is known about the
phenotype associated with GR_PRA1 in dogs beyond
ophthalmoscopic observations. Clinically the fundus ap-
pears identical to other forms of PRA and histological
and detailed ERG analysis has not been reported. In
addition, the age of onset is difficult to define, although
the age at which dogs with GR_PRA1 are diagnosed is
typically 6–7 years [4]. This is suggestive of a relatively
late-onset condition, a hypothesis consistent with the
findings in the SLC4A3 knockout mouse in which a se-
lective inner retina defect is followed by photoreceptor
degeneration at eight months [3]. Given the late onset of
clinical signs in the dog and mouse models, early onset
degenerations such as LCA are unlikely to be caused by
variants in SLC4A3. Alvarez and colleagues concluded
that their results in the knockout mouse linked aberrant
SLC4A3 to vitreoretinal degeneration [3]. While there
are similarities to vitreoretinal disorders, the data pre-
sented for the mouse phenotype is not pathognomonic
of a particular human phenotype. In addition, vitreoret-
inal disorders are rare and DNA samples may be difficult
to obtain. The other abnormalities reported by Alvarez
and colleagues were altered ERG and abnormal retinal
vessels, and these clinical features are shared by many
vitreoretinal and retinal degenerations. Currently there is
no evidence to suggest a human phenotype that would
be more likely to be caused by variants in SLC4A3 than
AR RP, but other phenotypes should not be excluded
from future studies.
Conclusions
Aberrant SLC4A3 has been shown to cause retinal dis-
ease in the mouse and dog, making the gene a strong
candidate for human retinal disease. Three rare variants
predicted to be potentially pathogenic were identified in
the SLC4A3 gene in a AR RP cohort, however all three
variants were present in the heterozygous state, and
therefore not disease-causing in isolation. Nevertheless,
we could not discount the possibility that these variants
have some role in the disease that we have yet to de-
cipher. The SLC4A3 gene remains an excellent candidate
gene for human retinal degeneration and the variants
identified will help to build a picture of its potential
contribution.
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